Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Inhibition, Psychological 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Nivolumab 3trametinib 2pertuzumab 2dabrafenib 2binimetinib 2Trastuzumab 2Azacitidine 2ulixertinib 1trastuzumab biosimilar HLX02 1tazemetostat 1sapanisertib 1romidepsin 1ribociclib 1relatlimab 1palbociclib 1osimertinib 1omipalisib 1margetuximab 1larotrectinib 1itacitinib 1ipatasertib 1erdafitinib 1defactinib 1copanlisib 1cobimetinib 1cc-486 1capivasertib 1bintrafusp alfa protein, human 1adavosertib 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × INCB039110 × Thoracic × Clear all
NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Incyte Corporation

Phase 2 Withdrawn
Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡